Tango Therapeutics (TNGX) Stock Price, News & Analysis

Company Overview

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $1.84 to $2.00
• 50-Day Range: $1.84 to $3.47
• 52-Week Range: $1.72 to $12.02
• Volume: 825,274 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $210.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.33
• Consensus Rating: Buy

Tango Therapeutics Stock Analysis - MarketRank™

Tango Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 751st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tango Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.19) to ($1.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tango Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tango Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tango Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.91% of the float of Tango Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tango Therapeutics has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Tango Therapeutics has recently increased by 18.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tango Therapeutics does not currently pay a dividend.

Dividend Growth

Tango Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.91% of the float of Tango Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tango Therapeutics has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Tango Therapeutics has recently increased by 18.52%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.27

News Sentiment

Tango Therapeutics has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Tango Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for TNGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,561.00 in company stock.

Percentage Held by Insiders

Only 6.30% of the stock of Tango Therapeutics is held by insiders.

Percentage Held by Institutions

78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNGX Stock Analysis - Frequently Asked Questions

How have TNGX shares performed this year?

Tango Therapeutics' stock was trading at $3.09 at the beginning of the year. Since then, TNGX shares have decreased by 36.7% and is now trading at $1.9550.
View the best growth stocks for 2025 here.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) released its quarterly earnings data on Thursday, February, 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.03. The business earned $4.12 million during the quarter, compared to analyst estimates of $7.84 million. Tango Therapeutics had a negative net margin of 284.42% and a negative trailing twelve-month return on equity of 49.64%.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' top institutional shareholders include TCG Crossover Management LLC (9.99%), Boxer Capital Management LLC (9.66%), Gilead Sciences Inc. (4.52%) and Farallon Capital Management LLC (3.72%). Insiders that own company stock include Rock Ventures Iv LP Third, Boxer Capital, Llc, Boxer Capital Management, Llc, Mva Investors, Llc, Daniella Beckman, Douglas Barry and Mace Rothenberg.
View institutional ownership trends.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tango Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 3/14/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNGX
• CIK: 1819133
• Web: www.tangotx.com
• Phone: 857-320-4900
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.33
• High Stock Price Target: $19.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +534.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-101,740,000.00
• Net Margins: -284.42%
• Pretax Margin: -283.95%
• Return on Equity: -49.64%
• Return on Assets: -32.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.00
• Quick Ratio: 8.00

Sales & Book Value

• Annual Sales: $42.07 million
• Price / Sales: 5.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.48 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 108,108,000
• Free Float: 100,651,000
• Market Cap: $210.27 million
• Optionable: Optionable
• Beta: 0.87